Clinical trials: Cancer Risk, open to volunteers
Rectal Cancers
Local Methylene Blue Injection for Prevention of Anastomotic Leakage and Permanent Stoma After Low Anterior Resection for Rectal Cancer
Rectal cancer surgery has become increasingly effective, allowing many patients to avoid permanent colostomy. However, anastomotic leakage remains one of the most serious complications after rectal cancer surgery, especially in…
- Trial name
- PKUCH-R10 (NCT07833319)
- Testing
- methylene blue injection
- Where
- China
- Volunteers
- 26 people
- Sponsor
- Peking University Cancer Hospital & Institute
Solid Tumors
Physician and Patient Preferences for Cell Therapies in Advanced Solid Tumors
Cell therapies - including chimeric antigen receptor T-cell (CAR-T) therapy, tumor-infiltrating lymphocyte (TIL) therapy, T-cell receptor-engineered T-cell (TCR-T) therapy, and natural killer (NK) cell therapy - are emerging…
- Trial name
- NCT07813000
- Testing
- Not applicable- observational study
- Where
- China
- Volunteers
- 1,020 people
- Sponsor
- Zhejiang University
Prostate Cancer, Prostate Adenocarcinoma
A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer
Researchers conducting this study hope to learn about the safety and effectiveness of combining two study drugs, relacorilant and enzalutamide, plus androgen deprivation therapy (ADT), also known as hormone therapy.
- Trial name
- NCT05726292
- Testing
- Relacorilant, Enzalutamide, Androgen Deprivation Therapy
- Where
- 4 sites in United States
- Volunteers
- 90 people
- Sponsor
- University of Chicago
Brain Cancer, Glioma
Magnetic Resonance (MR) Imaging to Determine High Risk Areas in Patients With Malignant Gliomas and to Design Potential Radiation Plans and to Examine Metabolite Changes in Gliomas and Other Solid Tumors
The researchers think that the use of advanced MR imaging may help people with this disease, because it may better predict areas within a malignant glioma (brain tumor) that are at a high risk of recurring.
- Trial name
- NCT00870129
- Testing
- MRI and advanced MRI sequences
- Where
- United States
- Volunteers
- 135 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Familial Pancreatic Cancer, BRCA1 Mutation
Registry of Subjects at Risk of Pancreatic Cancer
IRFARPC is a multicenter national registry designed to study the diagnosis and predisposing factors of subjects with an inherited increased risk for pancreatic cancer.
- Conditions
- Familial Pancreatic Cancer, BRCA1 Mutation, BRCA2 Mutation, Lynch Syndrome
- Trial name
- IRFARPC (NCT04095195)
- Testing
- MRCP, Endoultrasonography
- Where
- 4 sites in Italy
- Volunteers
- 1,000 people
- Sponsor
- Associazione Italiana per lo Studio del Pancreas
Colon Cancer, Neoadjuvant Therapies
Node-Sparing Low-Dose Radiotherapy Concurrent With Chemotherapy and PD-1 Inhibitor in pMMR/MSS High-Risk Locally Advanced Colon Cancer: A Prospective, Single-Arm, Phase II Trial
Most colorectal cancers belong to the microsatellite stable (MSS) or proficient mismatch repair (pMMR) subtypes, with limited response to PD-1 inhibitors.
- Conditions
- Colon Cancer, Neoadjuvant Therapies, Immune Checkpoint Therapy, Radiation Therapy
- Trial name
- MODIFI-L (NCT07279077)
- Testing
- Node-Sparing Low-Dose Radiotherapy Concurrent With Chemotherapy and PD-1 Inhibitor
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Hematologic Malignancies
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
SLS009 (formerly GFH009) is a potent and highly selective CDK9 inhibitor. In this study the safety, tolerability, and antitumor activity of single agent SLS009 are assessed in two dose escalation groups (Group 1 in patients with…
- Trial name
- NCT04588922
- Testing
- SLS009, venetoclax, azacitidine
- Where
- 32 sites in United States, China
- Volunteers
- 160 people
- Sponsor
- Sellas Life Sciences Group
Oropharyngeal Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma
Adaptive Treatment De-escalation in Favorable Risk HPV-Positive Oropharyngeal Carcinoma
This is a phase II clinical trial. The purpose of this study is to determine the feasibility of deescalating chemoradiation treatment based on mid-treatment tumor response determined by rapid nodal shrinkage and clearance of…
- Trial name
- NCT03215719
- Testing
- Standard Radiation Treatment, Dose-Deescalated Treatment, Cisplatinum
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- NYU Langone Health
Allogeneic Hematopoietic Stem Cell Transplantation, Allogeneic Stem Cell Transplantation
Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation
This is a prospective, single-arm, phase II study. Patients will be treated with an allogeneic stem cell transplantation (AHSCT) using fludarabine, melphalan and total body irradiation (TBI) conditioning with different melphalan…
- Conditions
- Allogeneic Hematopoietic Stem Cell Transplantation, Allogeneic Stem Cell Transplantation, Hematologic Malignancies
- Trial name
- ADAPT (NCT06028828)
- Testing
- Fludarabine, Melphalan, Total Body Irradiation
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of California, Irvine
Acute Myeloid Leukemia (AML), Maintenance Treatment
Lisaftoclax Plus Azacitidine Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia Patients at High Risk of Relapse
This study evaluates the efficacy and safety of maintenance therapy with lisaftoclax plus azacitidine after allogeneic hematopoietic stem cell transplantation (allo-HSCT) in adults with acute myeloid leukemia (AML) at high risk…
- Conditions
- Acute Myeloid Leukemia (AML), Maintenance Treatment, Hematopoetic Stem Cell Transplantation
- Trial name
- NCT07686965
- Testing
- Lisaftoclax Plus Azacitidine
- Volunteers
- 191 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Early Detection of Cancer
Understanding Information Preferences, Risk Perceptions, and Tradeoffs When Making Decisions About Multi-cancer Early Detection Tests
The goal of this clinical trial is to learn what people's informational preferences and risk perceptions are in regards to the use of multi-cancer early detection (MCED) tests.
- Trial name
- NCT07793539
- Testing
- Test Performance Information: High Detail, Test Performance Information: Low Detail, Diagnostic Workup Information: High Detail
- Where
- United States
- Volunteers
- 3,000 people
- Sponsor
- Trustees of Dartmouth College
Prostate Cancer, Prostate Cancer Patients
177Lu-PSMA-617 Combined With Darolutamide in Neoadjuvant Treatment of High-risk Localized Prostate Cancer: a Prospective, Single-arm, Multi-center Clinical Trial
The goal of this clinical trial is to explore the efficacy and safety of darolutamide combined with 177Lu-PSMA-617 in treating high-risk localized prostate cancer patients who are scheduled to undergo radical prostatectomy.
- Trial name
- IUNU-PC-123 (NCT07677566)
- Testing
- Darolutamide combined with 177Lu-PSMA-617
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Pancreatic Cancer
PANCREATIC DISEASE COHORT A Registry and Biospecimen Bank to Better Understand Pancreatic Disease
The specific aims of this project are to create a registry, as well as a biospecimen bank for individuals with pancreatic disease (e.g.
- Trial name
- NCT01102556
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Columbia University
Rectal Adenocarcinoma, High-Risk Cancer
NCT + PD1 + Ketogenic Diet and/or Vitamin C for LARC
To explore the efficacy and safety of adding a ketogenic diet and/or high-dose intravenous vitamin C to neoadjuvant short-course radiotherapy followed by mFOLFOX6 chemotherapy combined with serplulimab in patients with locally…
- Conditions
- Rectal Adenocarcinoma, High-Risk Cancer, MSS
- Trial name
- CRI-KEV (NCT07765667)
- Testing
- Short-Course Radiotherapy, PD-1 monoclonal antibody, mFOLFOX6 regimen
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Bladder (Urothelial, Transitional Cell) Cancer, Bladder Cancer
Xpert Bladder Monitor: a Non-Invasive Follow-Up Tool for Detecting Relapse in High Grade or High Risk Bladder Cancer
Main objectives: Qualitative and quantitative monitoring of recurrences in patients with a previous diagnosis of high-grade bladder cancer at high risk of persistence/recurrence.
- Conditions
- Bladder (Urothelial, Transitional Cell) Cancer, Bladder Cancer, Bladder Tumors, Bladder Cancer Recurrence
- Trial name
- LIBERO (NCT06751667)
- Testing
- Urinary biomarkers
- Volunteers
- 50 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Colorectal Cancer, Pancreatic Cancer
KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer
This clinical trial will utilize a neoantigen nanovaccine constructed from the bacterial membranes of an engineered Lactococcus lactis strain (FOLactis).
- Trial name
- NCT07353645
- Testing
- KRAS Neoantigen Nanovaccine
- Where
- China
- Volunteers
- 49 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
ctDNA, Chemotherapy
Randomized Study of Plasma ctDNA Methylation to Guide Adjuvant Chemotherapy Decisions in High-Risk T3N0 Colorectal Cancer
This study will utilize ctDNA methylation detection to evaluate patients with high-risk T3N0 stage II colorectal cancer who are ctDNA-positive one month after surgery.
- Conditions
- ctDNA, Chemotherapy, Colorectal Cancer
- Trial name
- CLEAR-02 (NCT07562711)
- Testing
- Capecitabine, FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)
- Where
- China
- Volunteers
- 340 people
- Sponsor
- Fudan University
Cervical Intraepithelial Neoplasia (CIN), Human Papillovirus
Local Hyperthermia for the Treatment of Cervical Persistent High-risk Infection
Human papillomavirus(HPV) infect epithelial cells and have the capacity to stimulate cell abnormal hyperplasia, especially by those high-risk HPV types.
- Trial name
- NCT07059819
- Testing
- Local hyperthermia device
- Where
- China
- Volunteers
- 400 people
- Sponsor
- First Hospital of China Medical University
Lung Cancer
Observational Study That Will Analyse the Spread and Stratification of Lung Cancer Risk Using Artificial Intelligence
Observational cohort study involving individuals of both sexes with a history of smoking, residing in municipalities in the state of Bahia and attended by the mobile unit, with the aim of evaluating the integration of artificial…
- Trial name
- ANASTASIA (NCT07617636)
- Where
- Brazil
- Volunteers
- 1,500 people
- Sponsor
- AstraZeneca
Prostate Cancer
Spanish Urological Association Registry of Patients on Active Surveillance
Description: Multicentre observational study, not randomized. Ambispective character (retro and prospective). Opened to any member of the Asociación Española de Urología (AEU), public and private medicine.
- Trial name
- NCT02865330
- Testing
- Registry
- Where
- Spain
- Volunteers
- 946 people
- Sponsor
- Fundación Instituto Valenciano de Oncología
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.